Journal Article Summary
The article examines the potential of metformin, a medication primarily used for managing type 2 diabetes, as a treatment for cancer within the framework of precision oncology. This topic is significant because metformin may offer a cost-effective and widely accessible option for enhancing cancer therapies, especially in low- and middle-income countries where expensive treatments are often out of reach. The review highlights metformin's ability to influence cellular metabolism and immune responses, which could help in inhibiting cancer growth and improving patient outcomes.
The authors conducted a comprehensive literature review, analyzing 63 studies from 2015 to 2025 that included preclinical, clinical, and translational research on metformin's anticancer effects. They found that while laboratory and animal studies consistently show metformin's ability to suppress cancer cell growth, the results in human patients are variable. This inconsistency is attributed to factors such as the biological diversity of tumors and the lack of effective biomarker-driven patient selection in clinical trials, indicating a need for more targeted research to identify which patients might benefit most from metformin.
Despite its promising potential, the article notes several limitations in the current understanding and application of metformin in oncology. These include the variability in patient responses, the absence of standardized biomarkers for patient selection, and the challenges of translating preclinical findings to clinical settings. Patients considering metformin for cancer treatment should discuss its use with their healthcare providers, particularly regarding its safety, potential interactions with other treatments, and the current state of research to ensure informed decision-making.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Khan Shehla Shafi, Rangraze Imran Rashid, Wali Adil Farooq, Jhancy Malay, Attia Rasha Aziz, Elshamly Hesham Amin Hamdy, Adam Shukri, Elbeshbeishy Rana Aly Mohamed. Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives. Medicina 2025. DOI: 10.3390/medicina61091577. PMID: 41010968. PMCID: PMC12471648.
Featured Pill Pals Product
Metformin 500 mg Immediate Release Tablets --- Ascend Pharma --- Generic for Glucophage
Metformin 500 mg Immediate Release Tablets — Ascend Pharma — Generic for Glucophage is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
